Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Hold" from Analysts

Key Points

• Sarepta Therapeutics has received a consensus rating of "Hold" from 29 analysts, with 6 sell ratings, 15 hold ratings, and 8 buy ratings.
• The average 12-month price target for Sarepta Therapeutics is $43.50, despite recent stock performance showing considerable volatility.
• In their latest earnings report, Sarepta posted an EPS of $2.02, exceeding expectations and reflecting a 68.4% increase in quarterly revenue year-over-year.

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have received a consensus recommendation of "Hold" from the twenty-nine analysts that are currently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $42.36.

Several equities research analysts have issued reports on SRPT shares. Piper Sandler lifted their target price on shares of Sarepta Therapeutics to $15.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Sarepta Therapeutics to $12.00 and gave the stock a "sell" rating in a research note on Friday, August 15th. Leerink Partners upped their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a "market perform" rating in a research note on Tuesday. UBS Group reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Finally, Barclays upgraded shares of Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 target price on the stock in a research report on Tuesday, July 29th.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently bought and sold shares of the company. Captrust Financial Advisors lifted its stake in Sarepta Therapeutics by 15.4% during the fourth quarter. Captrust Financial Advisors now owns 4,468 shares of the biotechnology company's stock worth $543,000 after purchasing an additional 597 shares during the last quarter. Cetera Investment Advisers grew its stake in Sarepta Therapeutics by 4.3% during the 4th quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock valued at $1,359,000 after acquiring an additional 463 shares in the last quarter. EP Wealth Advisors LLC grew its stake in Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after acquiring an additional 105 shares in the last quarter. Focus Partners Wealth lifted its holdings in shares of Sarepta Therapeutics by 30.0% during the 4th quarter. Focus Partners Wealth now owns 2,275 shares of the biotechnology company's stock valued at $277,000 after buying an additional 525 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC acquired a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $244,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Trading Down 2.9%

Shares of NASDAQ SRPT traded down $0.52 during mid-day trading on Monday, reaching $17.39. The company had a trading volume of 3,492,616 shares, compared to its average volume of 7,880,755. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $138.81. The business's 50-day moving average is $17.75 and its 200-day moving average is $41.28. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -19.99 and a beta of 0.49. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same period in the prior year, the firm posted $0.07 earnings per share. The company's quarterly revenue was up 68.4% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.